Coronavirus Clinical Trials Landscape - Analysis Using Excelra’s COVID-19 Biomarker Database

The ongoing COVID-19 pandemic is continuing to spread rapidly across the globe. As of 30th June 2020, the World Health Organization (WHO) has reported over 10 million cases and half a million deaths across 188 countries. Current clinical research is focused on accelerating the development of...

Read More

Excelra's COVID-19 Biomarker Database

COVID-19, a pandemic caused by the novel SARS-CoV-2 virus, has rapidly spread across the world in an unprecedented and devastating manner. Currently there are over 5 million confirmed cases and over 360 K deaths as reported by the World Health Organization. Furthermore, there are currently no...

Read More

Ruxolitinib - A Promising Drug Repurposing Candidate for COVID-19

Immune overreaction to a viral infection can lead to a Cytokine storm. It may also result in serious complications such as pneumonia and acute respiratory distress syndrome (ARDS). Ruxolitinib blocks cytokine mediated response by inhibiting the activation of JAK1 and JAK2, a critical...

Read More

Target Dossier

Target identification is an essential first step toward the discovery and development of any new therapeutic. Consequently, successful pharma organizations perform due diligence around a target of interest before embarking on the long, time-consuming, expensive and high-risk endeavor of drug...

Read More

Inhibition of SARS-CoV-2 Infection by Soluble Human ACE2

Reports suggest that SARS-CoV-2 virus has the ability to directly infect human blood vessel and kidney organoids. The use of clinical-grade recombinant human ACE2 (rhACE2) can reduce SARS-CoV-2 infection in cells and multiple human organoid models. Furthermore, the same study has also suggested...

Read More

Tocilizumab : Repurposing candidate for treatment of Cytokine Release Syndrome caused by SARS-CoV-2 infection.

Cytokine storm is an uncontrolled release of cytokines in the body in response to external stimuli leading to systemic inflammation. Ferrara et al. (1993) first coined the term “cytokine storm” in graft-versus-host disease. Approximately, 15.7% of COVID-19 patients develop severe pneumonia and...

Read More

Neutralizing Antibodies - An approach for COVID-19 treatment?

Immune or "convalescent” plasma refers to plasma collected from infected individuals, post resolution of infection. These infected individuals develop antibodies against the infection. Passive antibody administration through transfusion of convalescent plasma may offer a short-term strategy to...

Read More

GOBIOM - Understanding the platform's utility in clinical research and drug development

GOBIOM (Global Online Biomarker Database) is the world’s largest manually curated database of validated and putative biomarkers, providing critical insights into the relationship between biomarker and disease. GOBIOM as a one-stop platform provides clinical and pre-clinical information on...

Read More

Immunostimulation - A key driver to combat coronavirus

Although three human coronaviruses namely: SARS-CoV, MERS-CoV, and SARS-CoV-2 have hit mankind in last two decades, no vaccines have yet been developed against them. Vaccines are the most effective strategy for preventing infectious disease including viral diseases like COVID-19. Specialized...

Read More

Remdesivir- Potential Drug Repurposing Candidate for COVID-19

Mechanism of Action: RNA-dependent RNA polymerase (RdRp) inhibition

Read More